Business Context and Reporting Period
This Form 8-K reports on events occurring at the Annual Meeting of Shareholders for Lineage Cell Therapeutics, Inc. held on June 26, 2025. The filing details the election of directors, ratification of auditors, advisory vote on executive compensation, and the approval of an amendment to the company's equity incentive plan.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting results. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent 10-K or 10-Q filings for financial statements.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders at the Annual Meeting:
- Election of Directors: Shareholders elected seven nominees to the Board of Directors. All nominees received significant support, with votes "For" ranging from approximately 98.6 million to 99.4 million. Broker non-votes totaled 59,813,557 for all director elections.
- Ratification of Auditors: Shareholders ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The vote was 158,952,692 For, 912,282 Against, and 436,010 Abstentions.
- Executive Compensation (Say-on-Pay): Shareholders approved, on an advisory basis, the compensation of named executive officers. The vote was 96,071,162 For, 3,804,451 Against, and 611,814 Abstentions.
- Equity Incentive Plan Amendment: Shareholders approved an amendment to the 2021 Equity Incentive Plan (the "EIP Amendment"). This amendment increases the number of common shares available for issuance under the plan by 19,500,000. The vote was 88,575,737 For, 11,560,925 Against, and 350,765 Abstentions.
Guidance, Outlook, and Risks
This filing does not contain management guidance, financial outlook, or specific risk factors. The document notes that a more complete description of the EIP Amendment is available in the definitive proxy statement filed on April 29, 2025, which is incorporated by reference.
Key Facts for Investor Verification
- Verify the impact of the 19,500,000 share increase to the 2021 Equity Incentive Plan on potential future dilution.
- Review the Proxy Statement filed on April 29, 2025 for detailed terms of the EIP Amendment and executive compensation specifics.
- Note the significant number of broker non-votes (59,813,557) recorded for the director elections and executive compensation vote, indicating shares held in street name where brokers lacked discretionary voting authority.
- Confirm the tenure of the newly elected directors, who will serve until the 2026 annual meeting.